Moderna and Merck begin trial of mRNA-4157 and Keytruda combination for lung cancer

Moderna and Merck have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with Keytruda to treat non-small cell lung cancer (NSCLC).